Dashboard
Manage Tickers

IOVA IOVANCE BIOTHERAPEUTICS, INC.

Nasdaq iovance.com


$ 1.82 $ -0.02 (-1.09 %)    

Wednesday, 05-Nov-2025 19:00:53 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 622.38 $ 4.94 (0.8 %)
DIA $ 473.04 $ 2.23 (0.47 %)
SPY $ 677.28 $ 2.47 (0.37 %)
TLT $ 89.01 $ -0.57 (-0.64 %)
GLD $ 365.20 $ 0.10 (0.03 %)
$ 1.81
$ 1.83
$ 1.81 x 1,657
$ 1.92 x 30
$ 1.76 - $ 1.87
$ 1.64 - $ 12.51
17,496,571
na
654.96M
$ 1.31
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 02-27-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 02-28-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-10-2023 03-31-2023 10-Q
11 02-28-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 05-05-2022 03-31-2022 10-Q
15 02-24-2022 12-31-2021 10-K
16 11-04-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 02-25-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-06-2020 06-30-2020 10-Q
22 05-05-2020 03-31-2020 10-Q
23 02-25-2020 12-31-2019 10-K
24 11-04-2019 09-30-2019 10-Q
25 08-01-2019 06-30-2019 10-Q
26 05-07-2019 03-31-2019 10-Q
27 02-28-2019 12-31-2018 10-K
28 11-06-2018 09-30-2018 10-Q
29 08-07-2018 06-30-2018 10-Q
30 05-10-2018 03-31-2018 10-Q
31 03-12-2018 12-31-2017 10-K
32 11-02-2017 09-30-2017 10-Q
33 08-03-2017 06-30-2017 10-Q
34 05-03-2017 03-31-2017 10-Q
35 03-09-2017 12-31-2016 10-K
36 11-04-2016 09-30-2016 10-Q
37 08-09-2016 06-30-2016 10-Q
38 05-09-2016 03-31-2016 10-Q
39 03-11-2016 12-31-2015 10-K
40 11-06-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

examining-the-future-iovance-biotherapeuticss-earnings-outlook
Examining the Future: Iovance Biotherapeut...
11/05/2025 18:02:31

iovance-biotherapeutics-interim-data-from-phase-2-iov-lun-202-trial-of-lifileucel-monotherapy-for-previously-treated-patients-with-advanced-nonsquamous-nsclc-without-actionable-genetic-mutations-showed-26-objective-response-rate
Iovance Biotherapeutics' Interim Data From...
11/03/2025 12:03:33

The objective response rate (ORR) was 25.6% by RECIST v1.1 following one-time treatment with lifileucel monotherapy in patients...

hc-wainwright--co-maintains-buy-on-iovance-biotherapeutics-lowers-price-target-to-9
HC Wainwright & Co. Maintains Buy on Iovan...
10/29/2025 17:38:18

HC Wainwright & Co. analyst Joseph Pantginis maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and lowers the p...

keurig-dr-pepper-valneva-venu-holding-and-other-big-stocks-moving-lower-on-monday
Keurig Dr Pepper, Valneva, Venu Holding An...
08/25/2025 16:02:33

iovance-biotherapeutics--enters-amended-sale-agreement-with-jefferies-may-sell-up-to-350m-of-common-stock
Iovance Biotherapeutics Enters Amended Sa...
08/22/2025 21:23:44

-SEC Filing

intel-plymouth-industrial-reit-premier-and-other-big-stocks-moving-higher-on-tuesday
Intel, Plymouth Industrial REIT, Premier A...
08/19/2025 15:00:01

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
08/19/2025 12:08:33

why-palo-alto-shares-are-trading-higher-by-around-7-here-are-20-stocks-moving-premarket
Why Palo Alto Shares Are Trading Higher By...
08/19/2025 12:01:09

hc-wainwright--co-reiterates-buy-on-iovance-biotherapeutics-maintains-20-price-target
HC Wainwright & Co. Reiterates Buy on Iova...
08/19/2025 11:06:56

HC Wainwright & Co. analyst Joseph Pantginis reiterates Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and maintains $...

iovance-biotherapeutics-receives-health-canada-nocc-for-amtagvi
Iovance Biotherapeutics Receives Health Ca...
08/18/2025 20:24:10

First T cell therapy for a solid tumor cancer and first treatment option approved in Canada for advanced melanoma after anti-PD...

what-7-analyst-ratings-have-to-say-about-iovance-biotherapeutics
What 7 Analyst Ratings Have To Say About I...
08/08/2025 18:01:05

wells-fargo-maintains-overweight-on-iovance-biotherapeutics-lowers-price-target-to-14
Wells Fargo Maintains Overweight on Iovanc...
08/08/2025 15:30:29

Wells Fargo analyst Yanan Zhu maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and lowers the price target ...

pinterest-posts-downbeat-q2-earnings-joins-twilio-trade-desk-and-other-big-stocks-moving-lower-in-friday-pre-market-session
Pinterest Posts Downbeat Q2 Earnings, Join...
08/08/2025 12:43:36

chardan-capital-maintains-buy-on-iovance-biotherapeutics-lowers-price-target-to-20
Chardan Capital Maintains Buy on Iovance B...
08/08/2025 12:15:00

Chardan Capital analyst Geulah Livshits maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and lowers the price targ...

Core News & Articles
12 Health Care Stocks Moving In Friday's P...
08/08/2025 12:08:44

iovance-biotherapeutics-declines-29-in-premarket-trading-heres-whats-happening
Iovance Biotherapeutics Declines 29% In Pr...
08/08/2025 09:28:07

Iovance stock fell over 29% pre-market after Q2 results, despite reporting a strong revenue jump led by Amtagvi sales.

why-expedia-shares-are-trading-higher-by-around-18-here-are-20-stocks-moving-premarket
Why Expedia Shares Are Trading Higher By A...
08/08/2025 09:14:47

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
08/07/2025 21:08:09

iovance-biotherapeutics-affirms-fy2025-sales-guidance-of-250000m-300000m-vs-300184m-est
Iovance Biotherapeutics Affirms FY2025 Sal...
08/07/2025 20:14:16

Iovance Biotherapeutics (NASDAQ:IOVA) affirms FY2025 sales outlook from $250.000 million-$300.000 million to $250.000 million-$...

iovance-biotherapeutics-q2-eps-033-misses-029-estimate-sales-59952m-miss-69792m-estimate
Iovance Biotherapeutics Q2 EPS $(0.33) Mis...
08/07/2025 20:03:04

Iovance Biotherapeutics (NASDAQ:IOVA) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimat...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION